Kala Pharmaceuticals Inc Expected to Post Q1 2020 Earnings of ($0.92) Per Share (KALA)

Kala Pharmaceuticals Inc (NASDAQ:KALA) – Analysts at Wedbush issued their Q1 2020 EPS estimates for shares of Kala Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. Wedbush analyst L. Moussatos anticipates that the company will post earnings per share of ($0.92) for the quarter. Wedbush has a “Buy” rating and a $51.00 price target on the stock. Wedbush also issued estimates for Kala Pharmaceuticals’ Q2 2020 earnings at ($0.98) EPS, Q3 2020 earnings at ($0.56) EPS and Q4 2020 earnings at ($0.36) EPS.

Several other analysts have also recently issued reports on the stock. Jefferies Financial Group began coverage on shares of Kala Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research cut shares of Kala Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 5th. BidaskClub upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Kala Pharmaceuticals in a research report on Thursday, December 27th. Finally, ValuEngine cut shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Kala Pharmaceuticals has an average rating of “Buy” and a consensus price target of $20.58.

NASDAQ KALA opened at $8.41 on Thursday. Kala Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $18.30. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.27 and a current ratio of 6.34. The company has a market capitalization of $276.48 million, a price-to-earnings ratio of -3.39 and a beta of 1.73.

Several institutional investors have recently bought and sold shares of the company. RA Capital Management LLC raised its position in shares of Kala Pharmaceuticals by 114.7% during the 4th quarter. RA Capital Management LLC now owns 4,537,478 shares of the company’s stock valued at $22,188,000 after buying an additional 2,424,242 shares in the last quarter. BlackRock Inc. raised its position in shares of Kala Pharmaceuticals by 29.2% during the 4th quarter. BlackRock Inc. now owns 1,427,672 shares of the company’s stock valued at $6,980,000 after buying an additional 322,311 shares in the last quarter. Athyrium Capital Management LP purchased a new stake in shares of Kala Pharmaceuticals during the 4th quarter valued at $6,520,000. Vanguard Group Inc raised its position in shares of Kala Pharmaceuticals by 8.0% during the 3rd quarter. Vanguard Group Inc now owns 510,295 shares of the company’s stock valued at $5,036,000 after buying an additional 37,738 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Kala Pharmaceuticals by 8.0% during the 3rd quarter. Vanguard Group Inc. now owns 510,295 shares of the company’s stock valued at $5,036,000 after buying an additional 37,738 shares in the last quarter. Hedge funds and other institutional investors own 67.96% of the company’s stock.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: Stock Split

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit